| Project | Target | Indication | Development Stage |
|---|---|---|---|
| AZB102 | TRKA | TRKA Fusion Gene-Positive Cancers | In Vivo POC |
-
Mechanism of Action
AZB102 is designed to selectively target and inhibit TRKA, a mechanism related to cancers positive for the NTRK fusion gene.
-
Technical Advantage
· AZB102 is a highly selective kinase inhibitor for TRKA.
· AZB102 was confirmed to be a safe drug with high metabolic stability and no toxicity.
